Until some twelve years ago, approaches to asthma treatment were based on the phenotype of the patient and the degree of severity. With the appearance of the first monoclonal antibody, omalizumab, the possibility of providing customized treatment to the most severe patients began to be considered. In more than 50% of patients asthma is allergic; that is, it is an immunoglobulin E (IgE)-mediated disease. Therefore it seemed logical and reasonable to develop an antibody able to block IgE. Over the last twelve years, a great many studies have been published evaluating the efficacy and effectiveness of omalizumab. During this period, however, the indications for its administration have varied relatively little and the issue of when the drug should be withdrawn remains unresolved. This question is addressed in the present PhD thesis.The omalizumab prospectus has always stated that the drug is indicated in patients with severe allergic asthma caused by perennial allergens, but not by seasonal allergens. Our first study compares two cohorts of patients with severe allergic asthma: one sensitized to perennial allergens, and the other to seasonal allergens. The comparison of omalizumab treatment in the two groups shows that the clinical and biological behaviour is the same. The conclusion is therefore that patients with severe or very severe chronic asthma sensitized to seasonal allergens can also be treated with omalizumab. The second study, carried out over eight years, is the first assessment of a dose reduction protocol for omalizumab. The few studies of this kind performed to date have assessed only sudden withdrawal after a minimum of five years of treatment. Our protocol thus breaks new ground and solves two important doubts raised in the literature: first, it provides evidence that the drug can be withdrawn in a third of patients and that in others (approximately 20%) the dose can be reduced; and second, it establishes how to do this safely, because in our study we did not record any severe exacerbations. This thesis makes two significant contributions: first, it establishes a new indication for the drug; and second, it describes a procedure for the withdrawal of the drug in stable patients after a minimum treatment period of two years.
Preguntes no resoltes en l’asma al·lèrgica greu tractada amb omalizumab
Pomares Amigó, X. (Autor/a). 20 nov 2018
Tesis doctoral